Modeling the cancer patient with genetically engineered mice: Prediction of toxicity from molecule-targeted therapies

Cancer Cell

Volumn 5, Issue 2, 2004, Pages 115-120

  Roberts, Reade B ^a   Arteaga, Carlos L ^c   Threadgill, David W ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ALLELE; CANCER; CANCER PATIENT; CARDIOMYOPATHY; DEGENERATION; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; GENETIC ANALYSIS; GENETIC ENGINEERING; HOMOZYGOSITY; HUMAN; NONHUMAN; NULL ALLELE; PREDICTION; PRIORITY JOURNAL; REVIEW; TOXICITY; TUMOR;

ANIMALIA;

EID: 1442285909     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00032-7     Document Type: Review

References (63)

1. Ahmad S.R., Kortepeter C., Brinker A., Chen M., Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 25:2002;537-544.
2. Arteaga C.L., Baselga J. Clinical Trial Design and End Points for Epidermal Growth Factor Receptor-targeted Therapies. Implications for Drug Development and Practice Clin. Cancer Res. 9:2003;1579-1589.
3. Bannwarth B., Ravaud P., Dougados M. Cardiovascular thrombotic events and COX-2 inhibitors. results in patients with osteoarthritis receiving rofecoxib J. Rheumatol. 30:2003;421-422.
4. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., Kaye S.B., Gianni L., Harris A., Bjork T.et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:2002;4292-4302.
5. Britsch S., Li L., Kirchhoff S., Theuring F., Brinkmann V., Birchmeier C., Riethmacher D. The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev. 12:1998;1825-1836.
6. Busam K.J., Capodieci P., Motzer R., Kiehn T., Phelan D., Halpern A.C. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. 144:2001;1169-1176.
7. Chen B., Bronson R.T., Klaman L.D., Hampton T.G., Wang J.F., Green P.J., Magnuson T., Douglas P.S., Morgan J.P., Neel B.G. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat. Genet. 24:2000;296-299.
8. Chen W.S., Xu P.Z., Gottlob K., Chen M.L., Sokol K., Shiyanova T., Roninson I., Weng W., Suzuki R., Tobe K.et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15:2001;2203-2208.
9. Chene P. Inhibiting the p53-MDM2 interaction. an important target for cancer therapy Nat. Rev. Cancer. 3:2003;102-109.
10. Clark G.M., Perez-Soler R., Siu L.L., Gordon A., Santabarbara P. Rash severity is predictive of increased survival with erlotinib HCl. Proc. Am. Soc. Clin. Oncol. 22:2003;196.
11. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., Peterson K.L., Chen J., Kahn R., Condorelli G.et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8:2002;459-465.
12. Crone S.A., Negro A., Trumpp A., Giovannini M., Lee K.F. Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron. 37:2003;29-40.
13. Dinchuk J.E., Car B.D., Focht R.J., Johnston J.J., Jaffee B.D., Covington M.B., Contel N.R., Eng V.M., Collins R.J., Czerniak P.M.et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 378:1995;406-409.
14. Dumont N., Arteaga C.L. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell. 3:2003;531-536.
15. Egger B., Buchler M.W., Lakshmanan J., Moore P., Eysselein V.E. Mice harboring a defective epidermal growth factor receptor (waved-2) have an increased susceptibility to acute dextran sulfate-induced colitis. Scand. J. Gastroenterol. 35:2000;1181-1187.
16. Erickson S.L., O'Shea K.S., Ghaboosi N., Loverro L., Frantz G., Bauer M., Lu L.H., Moore M.W. ErbB3 is required for normal cerebellar and cardiac development. a comparison with ErbB2-and heregulin-deficient mice Development. 124:1997;4999-5011.
17. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442.
18. Fountzilas G., Papadimitriou C., Dafni U., Bafaloukos D., Skarlos D., Moulopoulos L.A., Razis E., Kalofonos H.P., Aravantinos G., Briassoulis E.et al. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer. a randomized study conducted by the Hellenic Cooperative Oncology Group J. Clin. Oncol. 19:2001;2232-2239.
19. Fruman D.A., Mauvais-Jarvis F., Pollard D.A., Yballe C.M., Brazil D., Bronson R.T., Kahn C.R., Cantley L.C. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat. Genet. 26:2000;379-382.
20. Garcia-Cao I., Garcia-Cao M., Martin-Caballero J., Criado L.M., Klatt P., Flores J.M., Weill J.C., Blasco M.A., Serrano M. Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21:2002;6225-6235.
21. Garofalo R.S., Orena S.J., Rafidi K., Torchia A.J., Stock J.L., Hildebrandt A.L., Coskran T., Black S.C., Brees D.J., Wicks J.R.et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J. Clin. Invest. 112:2003;197-208.
22. Gassmann M., Casagranda F., Orloff D., Simon H., Lai C., Klein R., Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 378:1995;390-394.
23. Hansen L.A., Alexander N., Hogan M.E., Sundberg J.P., Dlugosz A., Threadgill D.W., Magnuson T., Yuspa S.H. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am. J. Pathol. 150:1997;1959-1975.
24. Helmrath M.A., Erwin C.R., Warner M.D. A defective EGF-receptor in waved-2 mice attenuates intestinal adaptation. J. Surg. Res. 69:1997;76-80.
25. Hurwitz, H.I., Fehrenbacher, L., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Griffing, S., Novotny, W.F., Holmgren, E., and Kabbinavar, F. (2003). Bevacizumab prolongs survival in first-line colorectal cancer: Results of a phase III trial of bevacizumab in combination with bolus IFL as first-line therapy in subjects with metastatic CRC. Presented at ASCO Proceedings.
26. Jackson L.F., Qiu T.H., Sunnarborg S.W., Chang A., Zhang C., Patterson C., Lee D.C. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J. 22:2003;2704-2716.
27. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J., Jablons D.M., Langer C.L., Devore R.F., Gaudreault J., Damico L.A.et al. A Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel to carboplatin and paclitaxel alone in previously untreated locally advanced (IIIB) or metastatic non-small cell lung cancer. J. Clin. Oncol. in press:2004.
28. Joshi V., Ray G.S., Goldenring J.R. Inhibition of parietal cell acid secretion is mediated by the classical epidermal growth factor receptor. Dig. Dis. Sci. 42:1997;1194-1198.
29. Kanemura T., Suzuki H., Aoshiba K., Yokohori N., Nagai A. Acute lung injury in lung cancer patients treated with ZD1839 and bleomycin-induced pulmonary fibrosis in mice. Proc. Am. Soc. Clin. Oncol. 22:2003;652.
30. Lee K.F., Simon H., Chen H., Bates B., Hung M.C., Hauser C. Requirement for neuregulin receptor Erbb2 in neural and cardiac development. Nature. 378:1995;394-398.
31. Leveen P., Larsson J., Ehinger M., Cilio C.M., Sundler M., Sjostrand L.J., Holmdahl R., Karlsson S. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood. 100:2002;560-568.
32. Little C.C., Cloudman A.M. The occurrence of a dominant spotting mutation in the house mouse. Proc. Natl. Acad. Sci. USA. 23:1937;535-537.
33. Lowe C., Yoneda T., Boyce B.F., Chen H., Mundy G.R., Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc. Natl. Acad. Sci. USA. 90:1993;4485-4489.
34. Luetteke N.C., Phillips H.K., Qiu T., Copeland N.G., Earp H.S., Jenkins N.A., Lee D.C. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 8:1994;399-413.
35. Mann G.B., Fowler K.J., Gabriel A., Nice E.C., Williams R.L., Dunn A.R. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell. 73:1993;249-261.
36. Marshall E. Preventing toxicity with a gene test. Science. 302:2003;588-590.
37. Miettinen P.J., Berger J.E., Meneses J., Phung Y., Pedersen R.A., Werb Z., Derynck R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature. 376:1995;337-341.
38. Moon C., Oh Y., Roth J.A. Current status of gene therapy for lung cancer and head and neck cancer. Clin. Cancer Res. 9:2003;5055-5067.
39. Morham S.G., Langenbach R., Loftin C.D., Tiano H.F., Vouloumanos N., Jennette J.C., Mahler J.F., Kluckman K.D., Ledford A., Lee C.A.et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 83:1995;473-482.
40. Moss K.G., Toner G.C., Cherrington J.M., Mendel D.B., Laird A.D. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J. Pharmacol. Exp. Ther. 307:2003;476-480.
41. Mrsic M., Grgic M., Budisic Z., Podolski P., Bogdanic V., Labar B., Jakic-Razumovic J., Restek-Samarzija N., Gosev M. Trastuzumab in the treatment of advanced breast cancer. single-center experience Ann. Oncol. 12(Suppl 1):2001;S95-S96.
42. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S.et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28:2001;131-138.
43. Ozcelik C., Erdmann B., Pilz B., Wettschureck N., Britsch S., Hubner N., Chien K.R., Birchmeier C., Garratt A.N. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA. 99:2002;8880-8885.
44. Robert C., Spatz A., Faivre S., Armand J.P., Raymond E. Tyrosine kinase inhibition and grey hair. Lancet. 361:2003;1056.
45. Sage J., Miller A.L., Perez-Mancera P.A., Wysocki J.M., Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. 424:2003;223-228.
46. Saltz L., Kies M., Abbruzzese J.L., Azarnia N., Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. 22:2003;204.
47. Schwartzberg P.L., Stall A.M., Hardin J.D., Bowdish K.S., Humaran T., Boast S., Harbison M.L., Robertson E.J., Goff S.P. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell. 65:1991;1165-1175.
48. Sibilia M., Wagner E.F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science. 269:1995;234-238.
49. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M.et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
50. Soriano P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev. 8:1994;1888-1896.
51. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development. 124:1997;2691-2700.
52. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 64:1991;693-702.
53. Suzuki H., Aoshiba K., Yokohori N., Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res. 63:2003;5054-5059.
54. Teramoto S., Yamamoto H., Ouchi Y. Clinical efficacy and toxicity of gefitinib in patients with lung cancer. Lancet. 361:2003;1992-1993.
55. Terauchi Y., Tsuji Y., Satoh S., Minoura H., Murakami K., Okuno A., Inukai K., Asano T., Kaburagi Y., Ueki K.et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat. Genet. 21:1999;230-235.
56. Thaung C., West K., Clark B.J., McKie L., Morgan J.E., Arnold K., Nolan P.M., Peters J., Hunter A.J., Brown S.D.et al. Novel ENU-induced eye mutations in the mouse. models for human eye disease Hum. Mol. Genet. 11:2002;755-767.
57. Threadgill D.W., Dlugosz A.A., Hansen L.A., Tennenbaum T., Lichti U., Yee D., LaMantia C., Mourton T., Herrup K., Harris R.C.et al. Targeted disruption of mouse EGF receptor. effect of genetic background on mutant phenotype Science. 269:1995;230-234.
58. Troyer K.L., Luetteke N.C., Saxon M.L., Qiu T.H., Xian C.J., Lee D.C. Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking EGF, amphiregulin, and TGF-alpha. Gastroenterology. 121:2001;68-78.
59. Tybulewicz V.L., Crawford C.E., Jackson P.K., Bronson R.T., Mulligan R.C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 65:1991;1153-1163.
60. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C.et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 415:2002;45-53.
61. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349:2003;427-434.
62. Zambrowicz B.P., Sands A.T. Knockouts model the 100 best-selling drugs-will they model the next 100? Nat. Rev. Drug Discov. 2:2003;38-51.
63. Zhang M., Xuan S., Bouxsein M.L., von Stechow D., Akeno N., Faugere M.C., Malluche H., Zhao G., Rosen C.J., Efstratiadis A., Clemens T.L. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem. 277:2002;44005-44012.